Results 151 to 160 of about 7,833 (210)

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Next-generation Bruton's tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report. [PDF]

Ann Hematol
Chen L, Huang Y, Xu J, Huang S, Zhang Q, Hua F, Pan X, Mi JQ.   +7 more
europepmc   +1 more source

Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]

Cureus
Al-Shaker AN, Agarwal A, Saeed MT, Marney Z.   +3 more
europepmc   +1 more source

Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for Neuroinflammation. [PDF]

J Med Chem
Hopkins BT, Marx IE, Vandeveer HG, Nevalainen M, Basile R, Bajrami B, Choi CK, Grater RJ, Gu C, Hoemberger M, Kadakia E, Kapadnis SK, Liu Y, Ma B, Magee T, Metrick CM, Mingueneau M, Muste CA, Parker Harp CR, Prince RJ, Santoro JC, Schulz J, Sciabola S, Tang H, Wang T, Meissner R, Bohnert T.   +26 more
europepmc   +1 more source

Mechanisms of resistance to bruton's tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways. [PDF]

Ann Hematol
Dong X, Tang S, Chen M, Chen Q, Wang Y, Shi Y, Deng Y, Chen Y, He Z, Yu L, Wang C.   +10 more
europepmc   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy. [PDF]

Blood Cancer J
Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Danilov A, Argao C, Ruan J, Nizamuddin IA, Kahl BS, Grover NS, Khan NB, Pongas GN, Lossos IS, Ouchveridze E, Tun AM, Baidoun F, Alhaj Moustafa M, Harris ZI, Munoz JL, Young PR, Portell CA, Reagan PM, Ryan CE, Merryman RW, Velayati A, Greenwell IB, Gerber DG, Jain P, Wang ML, Ayyappan SR, Mou E, Banaszak LG, Pophali PA, Stack AC, Messmer MR, Narkhede MS, Mehta A, Moyo TK, Ghosh N, Bhansali RS, Barta SK, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P.   +55 more
europepmc   +1 more source

Delayed Cutaneous Ecchymosis with Bruton's Tyrosine Kinase Inhibitors and Breast Radiation: A Case Report. [PDF]

Adv Radiat Oncol
Kim J, Adrianzen Herrera D, Li PC.
europepmc   +1 more source

Pharmacologic Inhibition of Bruton's Tyrosine Kinase Attenuates Experimental Abdominal Aortic Aneurysms

JVS - Vascular Science, 2020
Baohui Xu, Yankui Li, Gang Li, Yingbin Ge, Jia Guo, Weirong Fang, Wei Wang, Fanru Shen, Takahiro Shoji, Toru Ikezoe, Xiaoya Zheng, Sihai Zhao, Xiaofeng Chen, Masaaki Miyata, Alan Daugherty, Hong Lu, Ronald L. Dalman   +16 more
doaj   +1 more source